EGFRvIII: An oncogene deletion mutant cell surface receptor target expressed by multiple tumour types

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 4, 2000, Pages 497-514

  Wikstrand, Carol J ^a   Sampson, John H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

breast carcinoma; EGFR; EGFRvIII; glioblastoma multiforme; immunotherapy; prostatic carcinoma; scFv; vaccination

Indexed keywords

EID: 0038195856     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.4.497     Document Type: Review

References (105)

1. DAVIS FG, PRESTON-MARTIN S: Epidemiology: incidence and survival. In: Russell and Rubinstein's Pathology of Tumours of the Nervous System (6th Edition). Bigner DD, McClendon RE, Bruner JM (Eds.), Oxford University Press, New York, USA (1998):5-46.
2. GROVAS A, GREMGEN A, RAUCK A et al.: The National Cancer Data Base Report on patterns of childhood cancers in the United States. Cancer (1997) 80:2321-2332.
3. WALKER MD, ALEXANDER E, HUNT WE et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. (1978) 49:333-343.
4. COKGOR I, AKABANI G, KUAN CT et al.: Phase I trial results of 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2000) (In Press).
5. GASPAR LE, FISHER BJ, MACDONALD DR etal: Supraten-torial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. (1992) 24:55-57.
6. WIKSTRAND CJ, REIST CJ, ARCHER GE, ZALUTSKY MR, BIGNER DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J. Neurovirol. (1998) 4:148-158.
7. WIKSTRAND CJ, COKGOR I, SAMPSON JH, BIGNER DD: Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. (1999) 18:451-464.
8. WIKSTRAND CJ, ZALUTSKY MR, BIGNER DD: Radiolabeled antibodies for therapy of brain tumors. In: Brain Tumour Immunotherapy. Liau LM, Becker DP, Cloughesy TF, Bigner DD (Eds.), Humana Press, Totowa, USA (2000) (In Press).
9. MERLINO GT, ISHII S, WHANG-PENG J et al.: Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol. Cell Biol. (1985) 5:1722-1729.
10. ARTEAGA CL, HURD SD, DUGGER TC, WINNIER AR, ROBERSTON JB: Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor a-Pseudomonas exotoxin 40 fusion protein. Cancer Res. (1994) 54:4703-4709.
11. GULLICK WJ, MARSDEN JJ, WHITTLE N, WARAD B, BOBROW L, WATERFIELD MD: Expression of epidermal growth factor receptors on human cervical, ovarian and vulval carcinomas. Cancer Res. (1986) 45:285-292.
12. OWENS OJ, STEWARD C, LEAKE RE, MCNICOL AM: A comparison of biochemical and immunohisto-chemical assessment of EGFR expression in ovarian cancer. Anticancer Res. (1992) 12:1455-1458.
13. HOLLSTEIN MC, SMITS AM, GALIANA C etal: Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res. (1988) 48:5119-5123.
14. RUSCH V, BASELGAJ, CORDON-CARDO C etal: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. (1993) 53:2379-2385.
15. AGOSTI RM, LEUTHOLD M, GULLICK WJ, YASARGIL MG, WIESTLER OD: Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch. A Pathol. Anat Histopathol. (1992) 420:321-325.
16. BIGNER SH, HUMPHREY PA, WONG AJ etal: Characteri zation of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. (1990) 50:8017-8022.
17. HUMPHREY PA, WONG AJ, VOGELSTEIN B etal: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. (1988) 48:2231-2238.
18. LIBERMANN TA, NUSBAUM HR, RAZON N etal: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 313:144-147.
19. SCHLEGEL J, MERDES A, STUMM G etal: Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer (1994) 56:72-77.
20. SCHWECHHEIMER K, HUANG S, CAVANEE WK: EGFR gene amplification- rearrangement in human glioblastomas. Int. J. Cancer (1995) 62:145-148.
21. TORP SH, HELSETH E, DALEN A, UNSGAARD G: Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother. (1991) 33:61-64.
22. WONG AJ, BIGNER SH, BIGNER DD, KINZLER KW, HAMILTON SR, BOGELSTEIN B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA (1987) 84:6899-6903.
23. EKSTRAND AJ, SUGAWA N, JAMES CD, COLLINS VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc. Natl Acad. Sci. USA (1992) 89:4309-4313.
24. SCHLEGEL J, STUMM G, BRANDLE K etal: Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol (1994) 22:201-207.
25. SAUTER G, MAEDA T, WALDMAN F, DAVIS RL, GEUERSTEIN BG: Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol (1996) 148:1047-1053.
26. GOIKE HM, ASPLUND AC, PETTERSSON EH, LIU L, SANOUDOU D, COLLINS VP: Acquired rearrangement of an amplified epidermal growth factor receptor (EGFR) gene in a human glioblastoma xenograft. J. Neuropathol Exp. Neurol (1999) 58:697-701.
27. DEBATISSE M, COQUELLE A, TOLEDO F, BUTTIN G: Gene amplification mechanisms: the role of fragile sites. Recent Results Cancer Res. (1998) 154:216-226.
28. CHAFFANET M, CHAUVIN C, LAINE M etal: EGFreceptor amplification and expression in human brain tumours. Eur. J. Cancer (1992) 28:11-17.
29. TSUGU A, KIJIMA H, YAMAZAKI H et al: Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma. Anticancer Res. (1997) 17:2225-2232.
30. GULLICK WJ, DOWNWARD J, PARKER PJ et al: The structure and function of the epidermal growth factor receptor studied by using anti-synthetic peptide antibodies. Proc.R. Soc. London Biol (1985) 2256:127-134.
31. WATERFIELD MD, MAYES ELV, STROOBANT P et al: A monoclonal antibody to the human epidermal growth factor receptor.J. Cell Biochem. (1982) 20:149-161.
32. SATO JD, KAWAMOTO T, LE AD, MENDELSOHN J, POLIKOFF J, SATO GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. (1983) 1:511-529.
33. KAWAMOTO T, SATO JD, LE A, POLIKOFF J, SATO GH, MENDELSOHN J: Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA (1983) 80:1337-1341.
34. MURTHY U, BASU A, RODECK U, HERLYN M, ROSS A, DAS M: Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. (1987) 252:549-560.
35. WIKSTRAND CJ, HALE LP, BATRA SK et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. (1995) 55:3140-3148.
36. HILLS D, ROWLINSON-BUSZA G, GULLICK WJ. Specific targeting of a mutant, activated EGFreceptor found in glioblastoma using a monoclonal antibody. Int. J. Cancer (1995) 63:537-543.
37. WIKSTRAND, CJ, FUNG, KM, TROJANOWSKI, JQ, MCLENDON, RE, BIGNER DD: Antibodies and molecular immunology. Immunohistochemistry and antigens of diagnostic significance. In: Russell and Rubinstein's Pathology of the Nervous System (6th Edition, Volume I). Bigner DD, Mclendon RE, Bruner JM (Eds.), Arnold Publishing, London, UK (1998):251-304.
38. DIETZMANN K, VON BOSSANYI P: Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study. ZentralblattPathol (1994) 140:335-341.
39. SCHOBER R, BILZER T, WAHA A et al: The epidermal growth factor receptor in glioblastoma: genomic amplification,protein expression and patient survival data in a therapeutic trial. Clin. Neuropathol (1995) 14:169-174.
40. BIGNER SH, BURGER PC, WONG AJ etal.: Gene amplification in malignant human gliomas: clinical and histopathological aspects. J. Neuropathol Exp. Neurol. (1988) 47:191-205.
41. HAWKINS RA, KILLEN E, WHITTLE IR: Epidermal growth factor receptors in intracranial and breast tumors: their clinical significance. Br. J. Cancer (1991) 63:553-560.
42. HURTTMR, MOOSSYJ, DONOVAN B, PELUSO M, LOCKER J: Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J. Neuropathol Exp. Neurol. (1992) 51:84-90.
43. KORSHUMOV A, GOLANOV A, SYCHEVA, R, PRONIN I: Prognostic value of tumor associated antigen immuno-reactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J. Clin. Pathol. (1999) 52:574-580.
44. NAGANE M, COUFAL F, LIN H etal: A common mutant epidermal growth factor receptor enhanced tumori-genicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. (1996) 56:5079-5086.
45. WATANABE K, TACHIBANA O, SATO K, YONEKAWA Y, KLEIHUES P, OHGAKI H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. (1996) 6:217-224.
46. KALOFONOS HP, PAWLIKOWSKA TR, HEMINGWAY A et al.: Antibody-guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. (1989) 30:1636-1645.
47. DADPARVAR S, KRISHNA L, MIYAMOTO C etal.: Indium-111-labeled anti-EGFR-425 scintigraphy in the detection of malignant gliomas. Cancer (1994) 73:884-889.
48. BRADY LW, MIYAMOTO C, WOO DV et al.: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. J. Radiat. Oncol. Biol. Phys. (1992) 22:225-230.
49. MIYAMOTO CT, BRADY LW, RACKOVER MA etal: The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Recent Results Cancer Res. (1996) 141:183-192.
50. COLCHER D, PAVLINKOVA G, BERESFORD G, BOOTH BJM, CHOUDHURY A, BATRASK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q.J. Nucl. Med. (1998) 42:225-241.
51. STRAGLIOTTO G, VEGA F, STASIECKI P, GROPP P, POISSON M, DELATTRE JY: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J. Cancer (1996) 32A:636-640.
52. WAKSAL HW: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. (1999) 18:427-436.
53. YANG X-D, JIA X-C, CORVALAN JRF etal: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236-1243.
54. EKSTRAND AJ, LONGO, N, HAMID, ML et al: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFRgene amplification. Oncogene (1994) 9:2313-2330.
55. NISHIKAWA R, JI, SC, HARMON, RC et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA (1994) 91:7727-7731.
56. BIGNER SH, BATRA, SK, RASHEED, BKA: Mechanisms of altered growth control. Cytogenetics, oncogenes and suppressor genes. In: Russell and Rubinstein's Pathology of the Nervous System (6th Edition). Bigner DD, Mclendon RE, Bruner JM (Eds.), Arnold Publishing, London, UK (1998):47-82.
57. EKSTRAND AJ, JAMES CD, CAVENEE WK, SELIGER B, PETTERSSON RF, COLLINS VP: Genes for epidermal growth factor receptor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. (1991) 51:2164-2172.
58. HUMPHREY PA, WONG AJ, VOGELSTEIN B et al.: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA (1990) 87:4207-4211.
59. YAMAZAKI H, OHBA Y, TAMAOKI N, SHIBUYA M: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. (1990) 81:773-779.
60. WIKSTRAND CJ, STANLEY SD, HUMPHREY PA et al.: Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J. Neuroimmunol. (1993) 46:165-174.
61. WIKSTRAND CJ, MCLENDON RE, FRIEDMAN AH, BIGNER DD: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. (1997) 57:4130-4140.
62. GARCIA DE PALAZZO IE, ADAMS GP, SUNDARESHAN P et al: Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. (1993) 53:3217-3220.
63. OLAPADE-OLAOPAEO, MOSCATELLO DK, MACKAYEHet al: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer (2000) 82:186-194.
64. SUÁREZ-QUIAN CA, BYERS SW: The distribution of epidermal growth factor receptor as a function of cell density, cell-cell adhesion and calcium in human (A-431) cells. Tissue Cell (1993) 25:1-17.
65. HERBST JJ, OPRESKO LK, WALSH BJ, LAUFFENBURGER DA, WILEY HS: Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J. Biol. Chem. (1994) 269:12865-12873.
66. HUANG HS, NAGANE M, KLINGBEIL CK et al.: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. (1997) 272:2927-2935.
67. WOLTJER RL, LUKAS TJ, STAROS JV: Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor. Proc. Natl. Acad. Sci. USA (1992) 89:7801-7805.
68. BATRA SK, CASTELINO-PRABHU S, WIKSTRAND CJ et al: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Diff. (1995) 6:1251-1259.
69. MOSCATELLO DK, MONTGOMERY RV, SUNDARESHAM P, MCDANEL H, WONG MY, WONG AJ: Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene (1996) 13:85-96.
70. CHU CT, EVERISS KD, WIKSTRAND CJ, BATRA SK, KUNG HJ, BIGNERDD: Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. (1997) 324:855-861.
71. PRIGENT SA, NAGANE M, LIN H et al: Enhanced tumori genic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol Chem. (1996) 271:25639-25645.
72. FELDKAMP MM, LAU N, RAK J, KERBEL RS, GUHA A: Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int.J. Cancer (1999) 81:118-124.
73. MOSCATELLO DK, HOLGADO-MADRUGA M, EMLET DR, MONTGOMERY RB WONG AJ: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. (1998) 273:200-206.
74. ANTONYAK MA, MOSCATELLO DK, WONG AJ: Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. (1998) 273:2817-2822.
75. NAGANE M, LEVITZKI A, GAZIT A, CAVENEE WK, HUANG HJ: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and capase-3-like proteases. Proc. Natl. Acad. Sci. USA (1998) 95:5724-5729.
76. WILLINGHAM MC, PASTAN IH, SAHAGIAN GG, JOURDIAN GW, NEUFELD EF: Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA (1981) 78:6967-6971.
77. WILLINGHAM MC, PASTAN IH: Transit of epidermal growth factor through coated pits of the golgi system. J. Cell Biol (1982) 94:207-212.
78. BEGUINOT L, LYALL RM, WILLINGHAM MC, PASTAN I: Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc. Natl. Acad. Sci. USA (1984) 81:2384-2388.
79. REIST CJ, ARCHER GE, KURPAD SN et al: Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. (1995) 55:4375-4382.
80. REIST CJ, BATRA SW, PEGRAM CN, BIGNER DD, ZALUTSKY MR: In vitroand in vivobehavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl. Med. Biol (1997) 24:637-647.
81. KUAN CT, REIST CJ, FOULON CF et al: 125I-labeled anti-epidermal growth factor receptor-vIII single chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin. CancerRes. (1999) 5:1539-1549.
82. KUAN CT, WIKSTRAND CJ, ARCHER GE et al.: Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. (2000) (Submitted).
83. LORIMER IAJ, DEPPLER-HAFKEMEYER A, BEERS RA, PEGRAM CN, BIGNER DD, PASTAN I: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. USA (1996) 93:14815-14820.
84. BEERS R, CHOWDHURY P, BIGNER DD, PASTAN I: Immunotoxins with increased activity against EGFRvIII-expressing cells produced by antibody phage display. Clin. Cancer Res. (2000) (In Press).
85. GOLDSTEIN JI, PREWETT M, ZUKLYS K, ROCKWELL P, MENDELSOHN J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
86. SAMPSON JH, ARCHER GE, ASHLEY DM et al.: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc. Natl. Acad. Sci. (1996) 93:10399-10404.
87. SAMPSON JH, CROTTY LE, LEE S et al: Unarmed, tumor-specific, monoclonal antibody effectively treats brain tumors through antibody-dependent cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA (2000) 97(13):7503-7508.
88. REIST CJ, ARCHER GE, WIKSTRAND CJ, BIGNER DD, ZALUTSKY MR: Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. (1997) 57:1510-1515.
89. REIST CJ, GARG PK, ALSTON KL, BIGNER DD, ZALUTSKY MR: Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3- pyridinecarboxylate. Cancer Res. (1996) 56:4970-4977.
90. SCHMIDT M, REISER P, HILLS D, GULLICK WJ, WELS W: Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int. J. Cancer (1998) 75:878-884.
91. SCHMIDT M, MAURER-GEBHARD M, GRONER B, KOHLER G, BROCHMANN-SANTOS G, WELS W: Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full length and oncogenic variant EGF receptors. Oncogene (1999) 18:1711-1721.
92. LORIMER IAJ, WIKSTRAND CJ, BATRA SK, BIGNER DD, PASTAN I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res. (1995) 1:859-864.
93. ARCHER GE, SAMPSON JH, LORIMER IAJ et al: Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single chain immunotoxin, MR-1. Clin. Cancer Res. (1999) 5:2646-2652.
94. HAN Y, CADAY CG, NANDA A, CAVENEE WK, HUANG HJ: Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild type epidermal growth factor receptors. Cancer Res. (1996) 56:3859-3861.
95. O'ROURKE DM, NUTE EJ, DAVIS JG et al: Inhibition of a naturally occurring EGFRoncoprotein by thep185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene (1998) 16:1197-1207.
96. MOSCATELLO DK, RAMIREZ G, WONG AJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immmuno-therapy of tumors. Cancer Res. (1997) 57:1419-1424.
97. SAMPSON JH, CROTTY LE, ARCHER GE, FRIEDMAN AH, FRIEDMAN HS, BIGNER DD: An EGFRvIII-specific peptide vaccine generates antitumor immunity through a humoral pathway. Neurooncology (1999) 1 :S103.
98. ASHLEY DM, SAMPSON JH, ARCHER GE, BATRA SK, BIGNER DD, HALE LP: Agenetically modified allogeneic cellular vaccine generates MHC class-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumor challenge. J. Neuroimmunol. (1997) 78:34-46.
99. WIKSTRAND CJ, COLE VR, CROTTY LE, SAMPSON JH, BIGNER DD. Anti-idiotype monoclonal antibody (mAb) vaccine approach to the therapy of variant epidermal growth factor receptor approach to the therapy of variant epidermal growth factor receptor (EGFRvIII)-expressing tumors. Neurooncology (1999) 1:S99.
100. BOWEN R, BONA C. Stimulation of lymphocytotoxic clones by anti-idiotypic antibodies: basis for development of idiotypic vaccines. Prog. Vaccinol. (1991) 3:8-21.
101. FERNANDEZ N, DUFFOUR MT, PERICAUDET M, LOTZE MT, TURSZ T, ZITVOGEL L: Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines CellMol. Ther. (1998) 4:53-65.
102. ASHLEY DM, FAIOLA B, NAIR S, HALE LP, BIGNER DD, GILBOA E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. (1997) 186:1177-1182.
103. ARCHER GE, HEIMBERGER AB, VILLAVICENCIO A et al: In vitro generation of dendritic cells from the peripheral blood of patients with malignant gliomas for antigen specific immunotherapy [abstract]. Neurooncology (1999) 1 :S104.
104. BRAIT M, TASSIGNON J, ISMAILIJ et al: Some thoughts on the future of idiotypic vaccines. Prog. Vaccinol (1991) 3:1-7.
105. FOULON CF, REIST CJ, BIGNER DD, ZALUTSKY MR: Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. (2000) (In Press).